pharmaceutical investing Data Safety Monitoring Board Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study
pharmaceutical investing BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
pharmaceutical investing BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+
pharmaceutical investing BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer
pharmaceutical investing BriaCell Opens First Canadian Site - Sunnybrook - for Pivotal Phase 3 Trial in Metastatic Breast Cancer
pharmaceutical investing BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT
pharmaceutical investing BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT
pharmaceutical investing BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT
biotech investing BriaCell Receives Positive Recommendation from Data Safety Monitoring Board for Phase 3 Study in Metastatic Breast Cancer
biotech investing BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+
Precious Metals & Critical Minerals Virtual Investor Conference Presentations Now Available for On-Demand Viewing
CoTec Holdings Corp. Announces Final Closing of Private Placement of Unsecured Convertible Debentures, Total Raise of $20 Million
